COLGATE PALMOLIVE CO·4

May 13, 4:46 PM ET

BOERNER CHRISTOPHER S. 4

4 · COLGATE PALMOLIVE CO · Filed May 13, 2026

Research Summary

AI-generated summary of this filing

Updated

Colgate Director Christopher Boerner Receives 1,383 Shares & 2,020 Options

What Happened
Christopher S. Boerner, a director of Colgate-Palmolive Co., was granted 1,383 shares and an award covering 2,020 derivative securities (stock options) on May 11, 2026 under the company's annual director incentive compensation plan. Both items are reported with an acquisition price of $0.00 (awarded as compensation); no cash was paid by the insider in this filing.

Key Details

  • Transaction date: May 11, 2026; Form 4 filed May 13, 2026 (timely filing).
  • Reported price: $0.00 for both the 1,383-share award and the 2,020-option award.
  • Shares/options received: 1,383 shares (award) and 2,020 options (derivative).
  • Shares owned following the transaction: Not specified in the filing.
  • Footnotes: F1 = annual director stock grant; F2 = annual director stock option grant; F3 = option vests (becomes exercisable) in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date.
  • Transaction code: A (award/grant).

Context These grants appear to be routine annual director compensation rather than an open-market purchase or sale. Options granted will vest over three years (first vesting around May 11, 2027), so they are not immediately exercisable or sold; such awards are common and do not by themselves indicate the insider’s trading view of the stock.

Insider Transaction Report

Form 4
Period: 2026-05-11
Transactions
  • Award

    Common Stock

    [F1]
    2026-05-11+1,3831,383 total
  • Award

    Stock Option (Right to Buy)

    [F2][F3]
    2026-05-11+2,0202,020 total
    Exercise: $86.74Exp: 2034-05-11Common Stock (2,020 underlying)
Footnotes (3)
  • [F1]Annual director stock grant under the issuer's incentive compensation plan.
  • [F2]Annual director stock option grant under the issuer's incentive compensation plan.
  • [F3]Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date.
Signature
/s/ Kristine Hutchinson, Attorney-in-Fact|2026-05-13

Documents

1 file
  • 4
    doc4.xmlPrimary